Last reviewed · How we verify
dHACM (AmnioWrap)
dHACM (dehydrated human amnion/chorion membrane) is a biologic tissue graft that provides a scaffold for wound healing and tissue regeneration through its extracellular matrix components.
dHACM (dehydrated human amnion/chorion membrane) is a biologic tissue graft that provides a scaffold for wound healing and tissue regeneration through its extracellular matrix components. Used for Diabetic foot ulcers, Chronic wounds, Surgical wounds.
At a glance
| Generic name | dHACM (AmnioWrap) |
|---|---|
| Sponsor | Louisiana State University Health Sciences Center in New Orleans |
| Drug class | Biologic tissue graft / Wound care product |
| Modality | Biologic |
| Therapeutic area | Wound Care / Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
dHACM is a decellularized, dehydrated allograft derived from human amniotic and chorionic membranes that contains native extracellular matrix proteins, growth factors, and cytokines. When applied to wounds or surgical sites, it acts as a biological dressing and scaffold to promote epithelialization, reduce inflammation, and facilitate tissue repair. The graft is resorbed over time as native tissue regenerates.
Approved indications
- Diabetic foot ulcers
- Chronic wounds
- Surgical wounds
- Burn wounds
Common side effects
- Infection at graft site
- Graft rejection or failure to integrate
- Allergic reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |